Regeneron Announces Investor Conference Presentations GlobeNewswire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on REGN
    Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
    1:20p ET March 22 '24 GlobeNewswire
    Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswireMarch 22, 2024

    NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

    If you own REGN please contact Justin Kuehn, Esq. by email at justin@kuehn.law or call (833) 672-0814. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

    Why Your Participation Matters:

    As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.(TM)

    For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

    Attorney advertising. Prior results do not guarantee similar outcomes.

    Contacts:Kuehn Law, PLLCJustin Kuehn, Esq.53 Hill Street, Suite 605 Southampton, NY 11968justin@kuehn.law(833) 672-0814

    COMTEX_449663937/2010/2024-03-22T13:20:43

    NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

    If you own REGN please contact Justin Kuehn, Esq. by email at justin@kuehn.law or call (833) 672-0814. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

    Why Your Participation Matters:

    As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.(TM)

    For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

    Attorney advertising. Prior results do not guarantee similar outcomes.

    Contacts:Kuehn Law, PLLCJustin Kuehn, Esq.53 Hill Street, Suite 605 Southampton, NY 11968justin@kuehn.law(833) 672-0814

    COMTEX_449663937/2010/2024-03-22T13:20:43

    Regeneron Reports First Quarter 2024 Financial and Operating Results
    6:30a ET May 2 '24 GlobeNewswire
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigatin...
    9:46p ET April 30 '24 ACCESSWIRE
    EYLEA(R) HD (aflibercept) Injection 8 mg Presentations at ARVO Reinfo...
    7:03a ET April 29 '24 GlobeNewswire
    Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response ...
    4:00p ET April 7 '24 GlobeNewswire
    Regeneron to Report First Quarter 2024 Financial and Operating Result...
    4:05p ET April 1 '24 GlobeNewswire
    SillaJen Submits CSR to the US FDA for REN026 Study in Patients with ...
    9:00a ET March 27 '24 BusinessWire
    Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to ...
    1:20p ET March 22 '24 GlobeNewswire
    Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to ...
    2:41p ET March 14 '24 Newsfile Corp
    High School Seniors Win $1.8 Million at Regeneron Science Talent Sear...
    11:56p ET March 12 '24 PR Newswire
    High School Seniors Win $1.8 Million at Regeneron Science Talent Sear...
    9:30p ET March 12 '24 GlobeNewswire

    Market data provided by News provided by